Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Altimmune Inc
(NQ:
ALT
)
7.470
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,128
Open
7.470
Bid (Size)
7.410 (1)
Ask (Size)
7.520 (2)
Prev. Close
7.470
Today's Range
7.470 - 7.470
52wk Range
2.090 - 14.84
Shares Outstanding
70,895,286
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
April 22, 2024
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio
Via
MarketBeat
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
April 20, 2024
Altimmune has a modest market cap but an incredibly promising GLP-1 drug.
Via
The Motley Fool
Performance
YTD
-28.99%
-28.99%
1 Month
-12.43%
-12.43%
3 Month
-25.60%
-25.60%
6 Month
+249.07%
+249.07%
1 Year
+35.33%
+35.33%
More News
Read More
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
April 11, 2024
Via
InvestorPlace
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
April 09, 2024
Via
The Motley Fool
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
April 09, 2024
Via
MarketBeat
Exposures
Product Safety
How Is The Market Feeling About Altimmune?
April 08, 2024
Via
Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
April 03, 2024
Via
Benzinga
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 28, 2024
Via
Benzinga
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
March 28, 2024
Via
Benzinga
ALT Stock Earnings: Altimmune Beats EPS for Q4 2023
March 27, 2024
Via
InvestorPlace
Altimmune's Earnings Outlook
March 26, 2024
Via
Benzinga
(ALT) - Analyzing Altimmune's Short Interest
March 22, 2024
Via
Benzinga
Here's How Much $100 Invested In Altimmune 5 Years Ago Would Be Worth Today
March 18, 2024
Via
Benzinga
Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review
March 28, 2024
Via
Investor's Business Daily
7 Stocks That Will Drive the Weight Loss Drugs Market
March 28, 2024
Via
MarketBeat
Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday?
March 27, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 27, 2024
Via
Benzinga
Earnings Scheduled For March 27, 2024
March 27, 2024
Via
Benzinga
Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'
March 19, 2024
Via
Benzinga
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
March 15, 2024
Via
The Motley Fool
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
March 03, 2024
Via
NewMediaWire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
March 03, 2024
Via
TheNewswire.com
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
March 01, 2024
Via
NewMediaWire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
March 01, 2024
Via
TheNewswire.com
Stock Market Rally At Highs After Big Earnings, Inflation Data: Weekly Review
March 01, 2024
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.